NCT04923984 Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
| NCT ID | NCT04923984 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | Subdural Hematoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-05-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2021-05-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Eligibility Criteria
Inclusion Criteria: \- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic. Exclusion Criteria: * If informed consent cannot be obtained from the patient or their substitute decision maker. * Known allergy to liquid embolic agent
Contact & Investigator
Jai Shankar, MD
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT04923984 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Subdural Hematoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04923984 currently recruiting?
Yes, NCT04923984 is actively recruiting participants. Contact the research team at shivajai1@gmail.com for enrollment information.
Where is the NCT04923984 trial being conducted?
This trial is being conducted at Winnipeg MB, Canada.
Who is sponsoring the NCT04923984 clinical trial?
NCT04923984 is sponsored by University of Manitoba. The principal investigator is Jai Shankar, MD at University of Manitoba. The trial plans to enroll 1,000 participants.